空气波压力治疗仪预防长期卧床患者下肢深静脉血栓形成的研究

目的 研究空气波压力治疗仪用于预防长期卧床患者下肢深静脉血栓形成(DVT)的效果.方法将62例长期卧床患者随机分为实验组及对照组,每组各31例,两组均采用常规预防方法.实验组每日使用空气波压力治疗仪治疗2次,30 min/次,10d为1疗程,连续应用2个疗程.对照组未使用治疗仪.对两组患者DVT发生率及肿胀、疼痛、舒适度方面进行观察比较.结果 实验组下肢DVT.的发生率明显低于对照组(P<0.01),且空气波压力治疗仪在消除肿胀、减轻疼痛及提高舒适度方面效果明显.结论 空气波压力治疗仪能有效预防长期卧床患者下肢DVT,且安全、舒适.     

空气波压力治疗仪在全髋关节置换术后预防下肢深静脉血栓形成中的应用

目的探讨空气波压力治疗仪在全髋关节置换术后预防下肢静脉血栓及减少肿胀中的应用效果。方法将本科2007年12月~2009年6月62例行全髋关节置换术后患者,按随机原则分为实验组和对照组,对照组采用肢体术后常规护理,实验组在对照组基础上加空气波压力治疗仪辅助治疗(30min/次,1次/d,7d为1个疗程,连续2个疗程),观察2组患者治疗前后肢体周径、血栓发生率和患肢冷感评分。结果经14d治疗后,实验组患者冷感评分降低,与治疗前和对照组比较差异有显著性意义(p<0.05);且实验组肢体周径缩小、血栓发生率明显低于对照组(p<0.05)。结论空气波压力治疗仪能有效预防全髋关节置换术后患者下肢深静脉血栓形成并减少肿胀,且安全舒适、经济实用。     

空气波压力治疗仪用于预防骨科卧床患者血栓形成的研究

目的:探讨空气波压力治疗仪(IPC)用于预防骨科卧床患者深静脉血栓形成(DVT)的效果。方法:将400例骨科卧床患者随机分为实验组及对照组各200例,两组均采用常规预防方法,实验组应用空气波压力治疗仪,2次/d,30min/次,10d为1疗程。对照组未使用治疗仪。对两组患者DVT发生率及肿胀、疼痛、舒适度方面进行观察比较。结果:实验组DVT的发生率明显低于对照组(P<0.01),且空气波压力治疗仪在消除肿胀、减轻疼痛及提高舒适度方面效果明显。结论:空气波压力治疗仪能有效预防骨科卧床患者下肢深静脉血栓形成,且安全舒适、经济适用。     

预见性护理联合空气压力波治疗仪在重型颅脑损伤患者中的应用

目的:探讨预见性护理联合空气压力波治疗仪在重型颅脑损伤患者中的应用及临床效果.方法:将100例重型颅脑损伤患者随机分为观察组和对照组各50例,对照组给予常规护理,观察组在此基础上给予预见性护理联合空气压力波治疗仪治疗,观察两组下肢深静脉血栓形成(DVT)和肢体肿胀情况.结果:两组DVT和肢体肿胀比较差异有统计学意义(P＜0.05).结论:预见性护理联合空气压力波治疗仪可有效减少重型颅脑损伤患者DVT,减轻肢体肿胀.     

空气波压力治疗仪对预防全髋关节置换术后并发深静脉血栓形成的影响

目的 探讨空气波压力治疗仪(IPC)对预防全髋关节置换术(THA)后并发下肢深静脉血栓(DVT)形成的治疗作用.方法 将62例THA后患者随机分为实验组和对照组,每组31例.实验组于手术麻醉消失后即介入IPC进行患肢的多腔气囊顺序充放气,形成对肢体和组织的循环压力;对照组则于手术麻醉消失后按常规方法进行患肢股四头肌舒缩及踝泵运动,术后2～7 d拔除创腔引流管后再加上膝关节的屈伸活动.结果 实验组DVT发生率为3.23%,对照组DVT发生率为22.58%,实验组预防DVT效果显著优于对照组(P＜0.05).结论 应用IPC对THA后患者患肢进行治疗可明显减少DVT的发生.     

空气波预防腰椎术后下肢深静脉血栓形成的效果

目的观察使用空气波治疗仪对腰椎术后病人肢体肿胀、疼痛、腓肠肌压痛情况的影响，以及预防下肢深静脉血栓（DVT）形成的临床效果。方法200例腰椎术后病人随机分为治疗组、对照组各100例。治疗组在临床常规手术后第1天，双下肢应用POWER空气波治疗仪治疗；对照组在临床常规手术后应用低分子肝素钙或低分子右旋糖苷等药物治疗。比较两组治疗后双下肢静脉管壁光滑度，肢体肿胀、疼痛程度。结果治疗1周后两组病人肢体肿胀、肢体疼痛和腓肠肌压痛情况比较，差异均有显著性（x^2=8．7～17．5，P〈0．01）。治疗组治疗2周后肢体重度肿胀、疼痛及DVT的发生率明显低于对照组（x^2=8．4、31．2，P〈0．01）。结论空气波治疗仪能明显减少腰椎术后病人下肢DVT的发生率，对早期DVT有很好的预防作用。     

空气波压力治疗仪预防脊柱骨折术后下肢深静脉血栓的效果

目的研究空气波压力治疗仪用于预防脊柱骨折术后患者下肢深静脉血栓形成(DVT)的效果。方法将80例脊柱骨折术后患者随机分为实验组和对照组,每组各40例,对照组采用常规预防方法,实验组除接受常规预防方法外,采用空气波压力治疗仪治疗(AWTT),观察两组患者DVT发生率。结果实验组下肢DVT发生率显著低于对照组(P<0.05)。结论空气波压力治疗仪能有效预防脊柱骨折术后患者下肢深静脉血栓形成。     

空气压力波治疗仪预防骨科DVT的疗效观察

目的:观察空气压力波治疗仪(IPC)预防骨科下肢深静脉血栓(DVT)的临床疗效.方法:将125例骨科术后患者随机分为两组,对照组(n=60)采用常规护理,观察组(n=65)在常规护理基础上使用IPC治疗和护理.术后2周比较两组患者DVT发生率及下肢肿胀和疼痛情况.结果:观察组DVT发生程度轻于对照组(P＜0.05).观察组下肢肿胀和疼痛发生率均低于对照组(P＜0.05).结论:IPC可降低骨科下肢深静脉血栓的发病率和缓解各临床不适症状,疗效显著,值得临床推广应用.     

空气波压力治疗在预防髋关节置换术后下肢深静脉血栓中的研究

目的探讨空气波压力治疗仪在髋关节置换术后预防下肢深静脉血栓形成中的作用。方法把80例髋关节置换术患者随机分为试验组40例,对照组40例。试验组术后4d采用空气波压力治疗仪治疗双下肢,对照组行常规治疗与护理联合个人行为功能锻炼。比较两组患者患肢疼痛程度、肿胀指数、凝血综合指数及下肢深静脉血栓的发生率,研究时间为10d。结果治疗后10d时试验组的疼痛分数为2.26±0.78、肿胀指数为5.66±2.06、凝血综合指数为2.36±1.08、下肢深静脉血栓形成的发生率为2.5%;对照组的疼痛分数为2.98±1.87、肿胀指数为6.98±1.99、凝血综合指数为3.18±1.38、下肢深静脉血栓形成的发生率为20.0%。试验组疼痛分数、肿胀指数、凝血综合指数及下肢深静脉血栓形成的发生率均明显低于对照组,差异有统计学意义(P0.05)。结论空气波压力治疗仪对预防髋关节置换术后下肢深静脉血栓形成有较好的效果,并且安全方便。     

空气波压力治疗预防全膝关节置换后下肢深静脉血栓

背景：大量文献研究表明,空气波压力治疗在预防髋部大手术后下肢深静脉血栓形成中有重要作用。目的：探讨空气波压力治疗仪对预防全膝关节置换后下肢深静脉血栓的效果。方法：80例全膝关节置换患者随机数字表法均分为试验组和对照组,对照组行常规治疗与护理加个人行为功能锻炼,试验组在对照组基础上,置换后第2天采用空气波压力治疗仪治疗双下肢;比较两组患者患肢肿胀指数、凝血综合指数及发生下肢深静脉血栓的例数。结果与结论：治疗后2周,试验组肿胀指数、凝血综合指数及发生下肢深静脉血栓的例数明显减少,其效果明显优于对照组,差异有显著性意义（P〈0.05）。全膝关节置换后早期应用空气波压力治疗仪能有效缓解患肢肿胀,改善凝血综合指数,改善患者的血凝状态,预防人工全膝关节置换后的下肢深静脉血栓形成。     

Diagnostic and therapeutic cholecystoscopy

Cholecystoscopy was performed in 52 patients at high risk of conventional surgical intervention after laparoscopic drainage of the gallbladder with a wide catheter. The results served the basis for diagnostic and therapeutic evaluation of the cholecystoscopic procedure. The author presents the techniques of diagnostic and therapeutic cholecystoscopy, bougienage of the external fistula produced when draining the bladder.     

Enhancing therapeutic impact and therapeutic alliance through electronic mail homework assignments

Homework assignments can enhance therapeutic impact and increase therapy effectiveness by encouraging patients to focus on therapy-related issues between sessions. Computer technology provides a new avenue for reporting, monitoring, and feedback of patient homework assignments through electronic mail (e-mail). In two case examples, e-mail was used as an extension of therapy to enhance patient involvement in treatment. In both cases, patient reports suggest that therapeutic alliance and therapeutic impact improved with the use of e-mail homework reporting. The costs and benefits of the use of e-mail as an adjunct to therapy are discussed.     

Hemorheology and therapeutic hemapheresis

Rheological parameters (plasma and blood viscosities, erythrocyte aggregation and deformability) are very relevant to a better understanding of the changes inflicted on the properties of blood in various hematological diseases (monoclonal gammopathies in particular). This study reports the measurement of rheological parameters (plasma and blood viscosity, RBC aggregation and deformability) in hematological disorders where abnormal blood properties have been described. All these diseases are treated by means of blood separators (therapeutic haemapheresis:plasma exchange, plasma processing, or erythrocyte exchange). We monitored plasma viscosity in 50 patients with monoclonal gammopathies: before and after each exchange (PE) or plasma processing (PP) sessions. Hyperviscosity was reduced in all cases after plasma exchange. Erythrocyte aggregation in gammopathies was also tested (15 multiple myelomas) treated by PE or PP, EA abnormalities and therapy-induced changes are described. EA is also modified by erythropheresis (seven sickle cell anemias). Measurement of rheological parameters are useful to the diagnosis of rheological abnormalities, as well as to assess the impact of therapeutic hemapheresis techniques like plasma exchange, plasma treatment, erythrocytapheresis.     

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

Most of the existing therapeutic antibodies that have been licensed and developed as medical agents are of the human IgG1 isotype, the molecular weight of which is ～ 150 kDa. Human IgG1 is a glycoprotein bearing two N-linked biantennary complex-type oligosaccharides bound to the antibody constant region (Fc), in which the majority of the oligosaccharides are core fucosylated, and it exercises the effector functions of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity through the interaction of the Fc with either leukocyte receptors (FcγRs) or complement. Recently, therapeutic antibodies have been shown to improve overall survival as well as time to disease progression in a variety of human malignancies, such as breast, colon and haematological cancers, and genetic analysis of FcγR polymorphisms of cancer patients has demonstrated that ADCC is a major antineoplasm mechanism responsible for clinical efficacy. However, the ADCC of existing licensed therapeutic antibodies has been found to be strongly inhibited by serum due to nonnpecific IgG competing for binding of the therapeutics to FcγRIIIa on natural killer cells, which leads to the requirement of a significant amount of drug and very high costs associated with such therapies. Moreover, enhanced ADCC of non-fucosylated forms of therapeutic antibodies through improved FcγRIIIa binding is shown to be inhibited by the fucosylated counterparts. In fact, non-fucosylated therapeutic antibodies, not including the fucosylated forms, exhibit the strongest and most saturable in vitro and ex vivo ADCC among such antibody variants with improved FcγRIIIa binding as those bearing naturally occurring oligosaccharide heterogeneities and artificial amino acid mutations, even in the presence of plasma IgG. Robust stable production of completely non-fucosylated therapeutic antibodies in a fixed quality has been achieved by the generation of a unique host cell line, in which the endogenous α-1,6-fucosyltransferase (FUT8) gene is knocked out. Thus, the application of non-fucosylated antibodies is expected to be a promising approach as next-generation therapeutic antibodies with improved efficacy, even when administrated at low doses in humans in vivo. Clinical trials using non-fucosylated antibody therapeutics are underway at present.     

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

Most of the existing therapeutic antibodies that have been licensed and developed as medical agents are of the human IgG1 isotype, the molecular weight of which is approximately 150 kDa. Human IgG1 is a glycoprotein bearing two N-linked biantennary complex-type oligosaccharides bound to the antibody constant region (Fc), in which the majority of the oligosaccharides are core fucosylated, and it exercises the effector functions of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity through the interaction of the Fc with either leukocyte receptors (FcgammaRs) or complement. Recently, therapeutic antibodies have been shown to improve overall survival as well as time to disease progression in a variety of human malignancies, such as breast, colon and haematological cancers, and genetic analysis of FcgammaR polymorphisms of cancer patients has demonstrated that ADCC is a major antineoplasm mechanism responsible for clinical efficacy. However, the ADCC of existing licensed therapeutic antibodies has been found to be strongly inhibited by serum due to nonnpecific IgG competing for binding of the therapeutics to FcgammaRIIIa on natural killer cells, which leads to the requirement of a significant amount of drug and very high costs associated with such therapies. Moreover, enhanced ADCC of non-fucosylated forms of therapeutic antibodies through improved FcgammaRIIIa binding is shown to be inhibited by the fucosylated counterparts. In fact, non-fucosylated therapeutic antibodies, not including the fucosylated forms, exhibit the strongest and most saturable in vitro and ex vivo ADCC among such antibody variants with improved FcgammaRIIIa binding as those bearing naturally occurring oligosaccharide heterogeneities and artificial amino acid mutations, even in the presence of plasma IgG. Robust stable production of completely non-fucosylated therapeutic antibodies in a fixed quality has been achieved by the generation of a unique host cell line, in which the endogenous alpha-1,6-fucosyltransferase (FUT8) gene is knocked out. Thus, the application of non-fucosylated antibodies is expected to be a promising approach as next-generation therapeutic antibodies with improved efficacy, even when administrated at low doses in humans in vivo. Clinical trials using non-fucosylated antibody therapeutics are underway at present.